Piomic Medical secured USD 25 million in growth financing led by Swisscanto to advance COMS One, its portable treatment for hard-to-heal wounds. Swisscanto committed CHF 10 million, with existing shareholders also participating. The financing brings Piomic’s total funding above USD 50 million across equity, convertible instruments and non-dilutive funding.
COMS One combines optical and magnetic stimulation. The proceeds support the MAVERICKS study, involving 224 patients at 30 US sites, and the European NAZARÉ trial, alongside preparations for a US approval filing. The device is CE-marked in Europe but remains investigational in the United States; its FDA Breakthrough Device designation is not marketing approval.
